
|Articles|May 15, 2018
NovaQuest Private Equity Acquires Majority Interest in Clinical Ink
Advertisement
Clinical Ink, the pioneering provider of eSource and next-generation ePRO/eCOA solutions for clinical development, announced that the private equity team at NovaQuest has acquired a majority of the outstanding shares of the company from existing investors and provided a substantial infusion of additional growth capital.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Applied Clinical Trials' 2025 State of the Industry Survey
2
Do Phase II Protocol Learnings Help Simplify Phase III Protocol Designs?
3
Beyond the Comment Section: Rebuilding Trust in Vaccines Through Conversation
4
ACT Brief Weekly Recap: Clinical Research Faces Funding Strain, Data Evolution, and a Shift in Outsourcing Models
5